Preclinical testing of radiopharmaceuticals for novel applications in HIV, bacterial and fungal infectious diseases

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 59, Issue 3, 2015, Pages 317-326

  Shah, M ^a   Garg, G ^a   Dadachova, E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Evaluation studies as topic; Infectious disease medicine; Radioimmunotherapy

Indexed keywords

AMPHOTERICIN; BISMUTH 213; DEOXYCHOLIC ACID; GLUCURONOXYLOMANNAN; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; RHENIUM 188; BISMUTH; RADIOISOTOPE; RHENIUM;

AJELLOMYCES CAPSULATUS; AJELLOMYCES DERMATITIDIS; ALPHA RADIATION; ANTHRAX; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BACILLUS ANTHRACIS; BACTERIAL INFECTION; CANDIDA ALBICANS; CANDIDIASIS; COCCIDIOIDES; COCCIDIOIDES POSADASSI; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG SCREENING; ELECTRON; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MYCOSIS; NEOSCYTALIDIUM DIMIDIATUM; NONHUMAN; OPPORTUNISTIC INFECTION; PARACOCCIDIOIDES BRASILIENSIS; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; SOUTH AMERICAN BLASTOMYCOSIS; SPOROTHRIX SCHENCKII; SPOROTRICHOSIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; ANIMAL; BACTERIAL INFECTIONS; C57BL MOUSE; CHEMISTRY; HIV INFECTIONS; MOUSE; MYCOSES; PRECLINICAL STUDY; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; BISMUTH; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG EVALUATION, PRECLINICAL; HIV INFECTIONS; HUMANS; MICE; MICE, INBRED C57BL; MYCOSES; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RHENIUM; TISSUE DISTRIBUTION;

EID: 84945186176     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Dadachova E, Nakouzi A, Bryan R, Casadevall A. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci USA 2003; 100: 10942-7.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525-30.
3. Larsen RA, Pappas PG, Perfect J, Aberg JA, Casadevall A, Cloud GA et al. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 2005; 49: 952-8.
4. Rhodes JC, Wicker LS, Urba WJ. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect Immun 1980; 29: 494-9
5. Jiang Z, Bryan RA, Morgenstern A, Bruchertseifer F, Casadevall A, Dadachova E. Treatment of early and established Cryptococcus neoformans infection with radiolabeled antibodies in immunocompetent mice. Antimicrob Agents Chemother 2012; 56: 552-4
6. Pai MP, Sakoglu U, Peterson SL, Lyons CR, Sood R. Characterization of BBB permeability in a preclinical model of cryptococcal meningoencephalitis using magnetic resonance imaging. J Cereb Blood Flow Metab 2009; 29: 545-53.
7. Bryan RA, Jiang Z, Howell RC, Morgenstern A, Bruchertseifer F, Casadevall A et al. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J Infect Dis 2010; 202: 633-7.
8. Clemons KV, Stevens DA. Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 1998; 42: 899-902.
9. Kakeya H, Miyazaki Y, Senda H, Senda H, Kobayashi T, Seki M et al. Efficacy of SPK-843, a novel polyene antifungal, in a murine model of systemic cryptococcosis. Antimicrob Agents Chemother 2008; 52: 1871-2.
10. Bicanic T, Muzoora C, Brouwer AE, Brouwer AE, Meintjes G, Longley N et al Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009; 49: 702-9.
11. Bryan RA, Jiang Z, Huang X, Morgenstern A, Bruchertseifer F, Sellers R et al. Radioimmunotherapy is effective against a high infection burden of Cryptococcus neoformans in mice and does not select for radiation-resistant phenotypes in cryptococcal cells. Antimicrob Agents Chemother 2009; 53: 1679-82.
12. Bryan RA, Huang X, Morgenstern A, Bruchertseifer F, Casadevall A, Dadachova E. Radio-fungicidal effects of external gamma radiation and antibody-targeted beta and alpha radiation on Cryptococcus neoformans. Antimicrob Agents Chemother 2008; 52: 2232-5.
13. Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, Liu Y et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One 2009; 4: e5392
14. Rachini A, Pietrella D, Lupo P, Torosantucci A, Chiani P, Bromuro C et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun 2007; 75: 5085-94.
15. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005; 202: 597-606.
16. Guimaraes AJ, Frases S, Gomez FJ, Zancope-Oliveira RM, Nosanchuk JD. Monoclonal antibodies to heat shock protein 60 alter the pathogenesis of Histoplasma capsulatum. Infect Immun 2009; 77: 1357-67.
17. Nosanchuk JD, Casadevall A. Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds Antimicrob Agents Chemother 2006; 50: 3519-28.
18. Bryan RA, Guimaraes AJ, Hopcraft S, Jiang Z, Bonilla K, Morgenstern A et al. Towards developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens. Mycopathologia 2012; 73: 463-71.
19. Dadachova E, Bryan RA, Apostolidis C, Morgenstern A, Zhang T, Moadel T et al. Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis 2006; 193: 1427-36.
20. Casadevall A, Mukherjee J, Devi SJ, Schneerson R, Robbins JB, Scharff MD. Antibodies elicited by a Cryptococcus neoformanstetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis 1992; 165: 1086-93.
21. Bryan RA, Zaragoza O, Zhang T, Ortiz G, Casadevall A, Dadachova E. Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryotic Cell 2005; 4: 465-75.
22. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci US A 2006; 103: 6841-6.
23. E. Dadachova, R. A. Bryan, X. Huang, G. Ortiz, T. Moadel, and A. Casadevall Comparative evaluation of capsular polysaccharide-specific IgM and IgG antibodies and F(ab)2 and Fab fragments as delivery vehicles for radioimmunotherapy of fungal infection. Clin Cancer Res 2007; 13: 5629s-35s.
24. Milenic DE, Yokota T, Filpula DR, Finkelman MA, Dodd SW, Wood JF et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991; 51: 6363-71.
25. Behr TM, Becker WS, Sharkey RM, Juweid ME, Dunn RM, Bair HJ et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J NuclMed 1996; 37: 829-33.
26. Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, Nosanchuk JS et al. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. Proc Natl Acad Sci US A 2004; 101: 14865-70.
27. Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A et al. A single treatment of 90Y-CHX-A C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004; 64: 6200-6.
28. Dadachova E, Burns T, Bryan RA, Apostolidis C, Brechbiel MW, Nosanchuk JD et al. Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob Agents Chemother 2004; 48: 1624-9.
29. Rivera J, Nakouzi AS, Morgenstern A, Bruchertseifer F, Dadachova E, Casadevall A. Radiolabeled antibodies toBacillus anthracis toxins are bactericidal and partially therapeutic in experimental murine anthrax. Antimicrob Agents Chemother 2009; 53: 4860-4868
30. Rivera J, Morgenstern A, Bruchertseifer F, Kearney JF, Turnbough CL Jr, Dadachova E et al. Microbicidal power of alpha radiation in sterilizing germinating Bacillus anthracis spores. Antimicrob Agents Chemother 2014; 58: 1813-5.
31. Estimated HIV incidence in the United States, 2007-2010. HIV Surveillance Supplemental Report. December 2012; 17(No. 4)
32. Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW et al. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med 2006; 3: e427.
33. Dadachova E, Kitchen SG, Bristol G, Baldwin GC, Revskaya E, Empig C et al. Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. PLoS One 2012; 7: e31866